Alzheimer Disease is a neurodegenerative disease that exhibits memory and cognitive deficits. Majority of research has targeted these late-stage biomarkers as treatment targets, yet all have failed in the clinical settings. Detection of early biomarkers is becoming imperative that can be easily and effectively used. fMRI is a quick and non-invasive procedure that can map whole brain activity. Here we use sensory evoked fMRI in a AD mouse model to show longitudinal changes in brain response that can be potential biomarkers for early AD.
No takes yet. Share an insight, caveat, or question.
You et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: